

+++ Press Release +++

FUJIFILM Healthcare launches the ARIETTA 65 IntuitiveFusion prostate biopsy system

Apr. 06, 2023

FUJIFILM Healthcare (headquartered in Minato-ku, Tokyo) today launches the "ARIETTA 65 IntuitiveFusion,"*1 an MRI-US fusion prostate biopsy*2 system that supports more efficient prostate biopsy. This prostate biopsy system is a combination of Fujifilm Healthcare's ARIETTA 65 ultrasound system and MedCom GmbH*3 (headquartered in Darmstadt, Federal Republic of Germany; hereinafter "MedCom")'s BiopSee software*4. The combination of the device and software realizes miniaturization and high operability, and supports more efficient prostate biopsy with a variety of functions that support MRI-US fusion prostate biopsy.

FUJIFILM Healthcare will exhibit this product at the 110th Annual Meeting of the Japanese Urological Association to be held at the Kobe Convention Center (Hyogo Prefecture) from April 20 to April 23.

Main Features

1) Compact size and high operability

The ARIETTA 65 IntuitiveFusion is a compact, space-saving MRI-US fusion prostate biopsy system that combines Fujifilm Healthcare's ARIETTA 65 ultrasound system and MedCom's BiopSee software. The BiopSee software can be operated and displayed on the monitor of the ARIETTA 65 for smooth operation. While conventional MRI-US fusion prostate biopsy systems require a separate dedicated device in addition to the diagnostic ultrasound system, the ARIETTA 65 IntuitiveFusion can be installed in a limited space thanks to its compact size. The ARIETTA 65 IntuitiveFusion can be installed in a limited space thanks to its compact size. The system can be used from ambulatory care to operation in an operating room where various equipment such as biomonitors and anesthesia machines are installed.

2) Prostate fusion puncture function compatible with prostate biopsy using BiopSee Software

The "ARIETTA 65 IntuitiveFusion" is equipped with a wide range of functions compatible with MRI-US fusion prostate biopsy. It contributes to the efficiency of prostate biopsy by supporting highly accurate puncture and precise tissue collection.

3) Pre-biopsy planning function

The biopsy pre-planning function allows the user to virtually set the location of the needle to be biopsied on the ultrasound image aligned with the MRI image.

4) Biopsy guide function

Based on the pre-planning, the biopsy can be navigated and supported by adjusting the probe position and guiding the needle insertion position with template coordinates (numbers of fixed devices in a grid that serve as a guide for the puncture position) and arrows.

5) Elastic fusion function

In addition to rigid fusion, the position of deformed tissue can be corrected in the MRI image according to the contours on the ultrasound image. By correcting the alignment due to deformation, the position can be intuitively grasped during biopsy.

6) Report function

All biopsied needle positions and displayed 2D and 3D cross-sectional images are output as a report. The results of the pathological examination of the tissue taken from the prostate biopsy (Gleason score, an evaluation index of malignancy) can also be recorded, which is expected to be applied to treatment planning, post-treatment follow-up, and active surveillance. 3.

7) Trans-perineal biopsy

The ARIETTA 65 IntuitiveFusion is compatible with transperineal biopsy, in which a needle is inserted between the scrotum and anus (perineum). Transperineal biopsy is a procedure that is said to have less risk of bleeding and infection compared to transrectal biopsy, in which a needle is inserted through the rectal wall from the anus.

Contact = Fujifilm Healthcare

Inquiry form: <https://www.fujifilm.com/fhc/ja/form/products>

1 MRI-US fusion prostate biopsy is one of the biopsy methods used for definitive diagnosis in patients suspected of having prostate cancer. The MRI image taken beforehand is fused with the ultrasound image and displayed in real time, and a needle biopsy of the prostate is performed under the guidance of the ultrasound image. By referring to the ultrasound image fused with the MRI image, the biopsy can target the lesion and is expected to improve the cancer detection rate, even in cases where the lesion is difficult to see in conventional prostate biopsy using only the ultrasound image as a reference.

**2 "ARIETTA 65 IntuitiveFusion" is the name of the MRI-US fusion prostate biopsy system that combines the ARIETTA 65 ultrasound system and BiopSee software.*

3 MedCom was established in 1997 and develops products in the field of medical imaging. The company provides innovative and advanced products with a focus on catheter-based interventions, surgical navigation, and cancer treatment.

4 Trade name: "BiopSee Software," which is installed on a general-purpose PC and mounted on an ultrasound device. Yoshida Denzai Kogyo (headquartered in Taito-ku, Tokyo) is the appointed manufacturer and distributor of this software. The company is a manufacturer of electrical and medical equipment founded in 1940.

Note: This Press Release was originally written in Japanese and has been translated into English.

[富士フイルムヘルスケア／前立腺生検システム「ARIETTA 65 IntuitiveFusion」\(アリエッタ65インテュイティブフュージョン\)を発売 | トピックス | 月刊新医療 \(newmed.co.jp\)](#)